Download PDF
CC BY 4.0 · Brazilian Journal of Oncology 2021; 17: e-20200042
DOI: 10.5935/2526-8732.20200042
Case Report
Oncological Surgery

Cancer occurrence in patients with inflammatory bowel disease in treatment with anti-TNF: report of three cases and literature review

Ocorrência de câncer em pacientes com doença inflamatória intestinal em tratamento com anti-TNF: relato de três casos e revisão da literatura

Lucas Camargo Gamba Martins do Amaral 
1   Unisul - Universidade do Sul de SC, Medicina - Tubarão - Santa Catarina
,
Luiz Henrique Locks Correa
2   Hospital Nossa Senhora da Conceição, Serviço de Cirurgia - Tubarão - Santa Catarina - Brazil
,
Cassiano Coral Accord
2   Hospital Nossa Senhora da Conceição, Serviço de Cirurgia - Tubarão - Santa Catarina - Brazil
,
Thamy dos Santos
2   Hospital Nossa Senhora da Conceição, Serviço de Cirurgia - Tubarão - Santa Catarina - Brazil
,
Beatriz de Oliveira Kock
2   Hospital Nossa Senhora da Conceição, Serviço de Cirurgia - Tubarão - Santa Catarina - Brazil
,
Kaiser de Souza Kock
1   Unisul - Universidade do Sul de SC, Medicina - Tubarão - Santa Catarina
› Author Affiliations Financial support: none to declare.
› Further Information
   Permissions and Reprints All articles of this category

ABSTRACT

Case report of three patients with inflammatory bowel disease who underwent treatment with biology therapy and developed respectively: non-Hodgkins lymphoma, colorectal adenocarcinoma, and cholangiocarcinoma after long-term follow-up. They demonstrated that data are currently inconclusive about the development of long-term anti-TNF neoplasias.

RESUMO

Relato de caso de três pacientes com doença inflamatória intestinal que realizaram tratamento com terapia biológica e desenvolveram, respectivamente: linfoma nãoHodgkin, adenocarcinoma colorretal e colangiocarcinoma, após acompanhamento a longo prazo. Eles demonstraram que os dados atualmente são inconclusivos sobre o desenvolvimento de neoplasias anti-TNF a longo prazo.

Keywords:

Inflammatory bowel diseases - Tumor necrosis factors - Lymphoma - NonHodgkin - Cholangiocarcinoma.

Descritores:

Doenças inflamatórias intestinais - Fatores de necrose tumoral - Linfoma não-Hodgkin - Colangiocarcinoma.


Publication History

Received: 12 December 2019

Accepted: 01 October 2020

Article published online:
08 January 2021

© 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

Bibliographical Record
Lucas Camargo Gamba Martins do Amaral, Luiz Henrique Locks Correa, Cassiano Coral Accord, Thamy dos Santos, Beatriz de Oliveira Kock, Kaiser de Souza Kock. Cancer occurrence in patients with inflammatory bowel disease in treatment with anti-TNF: report of three cases and literature review. Brazilian Journal of Oncology 2021; 17: e-20200042.
DOI: 10.5935/2526-8732.20200042
 

  • REFERENCES

  • Cardozo WS, Sobrado CW.. Doença inflamatória intestinal. 2a . Barueri: Manole;; 2014. 2.
    Search in Google Scholar
  • Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M. et al Second European evidence- based consensus on the diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2012; Dec; 6 (10) 991-1030
    Search in Google Scholar
  • Raval G, Mehta P. TNF-a. inhibitors: are they carcinogenic?. Drug Healthc Patient Saf 2010; 2: 241-247
    Search in Google Scholar
  • Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF. et al The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; Feb; 4 (01) 28-62
    Search in Google Scholar
  • Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J. et al Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; Jan; 146 (01) 96-109.e1
    Search in Google Scholar
  • Sandborn WJ, Gasink C, Gao LL, Blank M, Johanns J, Guzzo C. et al Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; Oct; 367 (16) 1519-1528
    Search in Google Scholar
  • Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T.. Risk of extra-intestinal cancer in inflammatory bowel disease: metaanalysis of population-based cohort studies. Am J Gastroenterol 2010; Jul; 105 (07) 1480-1487
    Search in Google Scholar
  • Sultan K, Shapira J.. Inflammatory bowel disease and lymphoma: a comprehensive review for the general gastroenterologist. Pract Gastroenterol 2012; Aug; 13
    Search in Google Scholar
  • Cohen RB, Dittrich KA.. Anti-TNF therapy and malignancy-a critical review. Can J Gastroenterol Hepatol 2001; Jun; 15 (06) 376-384
    Search in Google Scholar
  • O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Hardwood C. et al Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; Sep; 309 (5742) 1871-1874
    Search in Google Scholar
  • Beaugerie L.. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?. Gut 2012; Apr; 61 (04) 476-483
    Search in Google Scholar
  • Molnár T, Farkas K, Nagy F, Szepes Z, Wittmann T.. Lymphomas in two IBD patients treated with anti- TNF-a mono or combination therapy: is hepatosplenic lymphoma really the “old maid”?. Inflamm Bowel Dis 2011; Sep; 17 (09) 2025-2026
    Search in Google Scholar
  • Mourabet ME, Hashash JG, Sun NH, Issa M, Katz JA, Regueiro M. et al Clinical course of Crohn's disease following treatment of lymphoma. Inflamm Bowel Dis 2011; Jun; 17 (06) 1265-1269
    Search in Google Scholar
  • Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI.. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of populationbased cohort studies. Am J Gastroenterol 2005; Dec; 100 (02) 2724-2729
    Search in Google Scholar